The Supreme Court faces an emergency request from abortion pill mifepristone manufacturer Danco Laboratories after a 5th Circuit ruling reinstated in-person prescription requirements.
A federal appeals court temporarily halted a Food and Drug Administration regulation that has greatly expanded access to the abortion pill mifepristone.
The Fifth Circuit Court's ruling, which is being appealed, reinstates a requirement that patients visit a health care provider in person to obtain mifepristone, upending abortion access in the United States.
